| Literature DB >> 12852746 |
Keith G Watson1, Renee N Brown, Rachel Cameron, David K Chalmers, Stephanie Hamilton, Betty Jin, Guy Y Krippner, Angela Luttick, Darryl B McConnell, Phillip A Reece, Jane Ryan, Pauline C Stanislawski, Simon P Tucker, Wen-Yang Wu, Dale L Barnard, Robert W Sidwell.
Abstract
A series of capsid-binding compounds was screened against human rhinovirus (HRV) using a CPE based assay. The ethyl oxime ether 14 was found to have outstanding anti-HRV activity (median IC(50) 4.75 ng/mL), and unlike the equivalent ethyl ester compound 3 (Pirodavir), it has good oral bioavailability, making it a promising development candidate. Compound 14 illustrates that an oxime ether group can act as a metabolically stable bioisostere for an ester functionality.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12852746 DOI： 10.1021/jm0202876
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446